Expertise in
8
conditions

Dr. Mohamad A. Salkeni

Oncology | Internal Medicine
Virginia Cancer Specialists
8613 Route 29, 
Fairfax, VA 
Accepting New Patients
Offers Telehealth
Expertise in
8
conditions
Virginia Cancer Specialists
8613 Route 29, 
Fairfax, VA 

Overview

Mohamad Salkeni is an Oncologist and an Internal Medicine provider practicing medicine in Fairfax, Virginia.

Dr. Salkeni is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Inflammatory Breast Cancer, Angiosarcoma, Breast Cancer, and Paget Disease of the Breast.

He is actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 4 clinical trials. Dr. Salkeni is currently accepting new patients.

Graduate Institution

University Of Damascus Faculty Of Medicine

Residency

Saint Louis University School of Medicine Training Specialty: Internal Medicine 11/27/2006 - 11/27/2009

Specialties

Oncology
Internal Medicine

Licenses

Internal Medicine in VA

Fellowships

University of Cincinnati Medical Center Training Specialty: 12/1/2009 - 11/30/2012

Hospital Affiliations

Inova Fairfax Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Innovation Health
  • HMO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Virginia Cancer Specialists
8613 Route 29, Fairfax, VA 22031

Additional Areas of Focus

Dr. Salkeni has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Biological, Drug
Study Drugs: Paclitaxel, Pelareorep, Avelumab
Study Phase: Phase 2
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: March 07, 2023
Intervention Type: Drug
Study Drugs: Ladiratuzumab vedotin, Trastuzumab
Study Phase: Phase 1
View 3 Less Clinical Trials

23 Total Publications

Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors.
Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors.
Journal: Cancer chemotherapy and pharmacology
Published: November 21, 2025
Similar Doctors
Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

MedStar Georgetown University Hospital

3800 Reservoir Rd NW, 
Washington, DC 
 (10.6 miles away)
202-444-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bruce Cheson is an Oncologist practicing medicine in Washington, Washington, D.c.. Dr. Cheson is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Follicular Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Non-Hodgkin Lymphoma. Dr. Cheson is currently accepting new patients.

Expertise in
88
conditions
Expertise in
88
conditions
Referral may be required

Virginia Cancer Specialists

8613 Route 29, 
Fairfax, VA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexander Spira is an Oncologist practicing medicine in Fairfax, Virginia. Dr. Spira is highly rated in 88 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Spira is currently accepting new patients.

Expertise in
18
conditions
Dr. Brigitte C. Widemann
Hematology | Oncology
Expertise in
18
conditions
Dr. Brigitte C. Widemann
Hematology | Oncology
Referral may be required

Office

8906 Bradmoor Dr, 
Bethesda, MD 
 (12.4 miles away)
301-496-7387
Languages Spoken:
English

Brigitte Widemann is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Widemann is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Medullary Thyroid Carcinoma, and Thyroidectomy.

Frequently Asked Questions about Dr. Mohamad A. Salkeni

Is Dr. Mohamad A. Salkeni a top-rated expert for Inflammatory Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mohamad A. Salkeni is classified as an Distinguished expert for Inflammatory Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mohamad A. Salkeni specialize in?

While Dr. Mohamad A. Salkeni is a Oncology, they have specific expertise in Inflammatory Breast Cancer, Angiosarcoma, and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Mohamad A. Salkeni participate in research or clinical trials?

Yes. Dr. Mohamad A. Salkeni has published 23 articles and abstracts on conditions like Inflammatory Breast Cancer. You can view a list of Dr. Mohamad A. Salkeni's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mohamad A. Salkeni accept my insurance?

Dr. Mohamad A. Salkeni accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Salkeni's expertise for a condition
ConditionClose
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile